Abcam, ab250986, Anti-ECH1 antibody [EPR15449(B)] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal ECH1 antibody. Carrier free. Suitable for IP, WB, IHC-P, ICC/IF, Flow Cyt (Intra) and reacts with Human samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR15449(B),
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:WB, ICC/IF, Flow Cyt (Intra), IP, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab250986 is the carrier-free version of
ab189255
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
ECH1 also known as Delta(35)-Delta(24)-dienoyl-CoA isomerase is a mitochondrial protein with a mass of approximately 31 kDa. It is expressed in a wide variety of tissues including high levels in the liver heart and muscle. This protein plays an important role in the beta-oxidation of unsaturated fatty acids inside mitochondria by catalyzing the conversion of 35-dienoyl-CoA to 24-dienoyl-CoA. Because of this function ECH1 contributes to the efficient metabolism of fatty acids.
Biological function summary
The ECH1 protein facilitates the breakdown and utilization of unsaturated fatty acids thereby providing energy for cellular processes. It acts independently and is not a part of a large protein complex. Mitochondria rely on ECH1 to handle specific intermediates in fatty acid metabolism which impacts how cells manage their energy resources. This makes ECH1 essential for maintaining energy homeostasis particularly during periods of increased metabolic demand.
Pathways
ECH1 is integral to the mitochondrial fatty acid beta-oxidation pathway. This pathway is important for converting fatty acids into acetyl-CoA units which then enter the Krebs cycle for further energy production. ECH1 interacts with other proteins like ACAA2 which contributes to the final step of fatty acid degradation. Alongside this it aligns with the peroxisomal biogenesis pathway influencing the balance between metabolic processes within mitochondria and peroxisomes.
ECH1 activity impacts conditions such as metabolic syndrome and inherited disorders of mitochondrial fatty acid oxidation including Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency. Changes in the function or expression of ECH1 can lead to accumulation of fatty acid intermediates causing cellular dysfunction. In diseases where energy balance is disrupted like metabolic syndrome ECH1's interaction with proteins like HADHA which assists in the final steps of beta-oxidation becomes significant for understanding and potentially targeting treatments.